Valneva SE (VALN) stock
VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.34−0.23 (-4.04%)
Close on Nov 18, 2026Market cap $463.35MP/E –Yield –
Valneva revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Valneva's revenue for the twelve months ending Jun 30, 2026 was €142.94M, down 27.2% year over year. For fiscal 2025 it was €174.66M, up 3.0% from the year before. The highest annual figure on record is €361.30M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €174.66M | +3.0% |
| FY2024 | Dec 31, 2024 | €169.58M | +10.3% |
| FY2023 | Dec 31, 2023 | €153.71M | -57.5% |
| FY2022 | Dec 31, 2022 | €361.30M | +3.8% |
| FY2021 | Dec 31, 2021 | €348.09M | +215.5% |
| FY2020 | Dec 31, 2020 | €110.32M | -12.6% |
| FY2019 | Dec 31, 2019 | €126.20M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €34.94M | -27.7% |
| Q1 FY2026 | Mar 31, 2026 | €30.90M | -37.2% |
| Q4 FY2025 | Dec 31, 2025 | €47.69M | -9.9% |
| Q3 FY2025 | Sep 30, 2025 | €29.41M | -35.8% |
| Q2 FY2025 | Jun 30, 2025 | €48.33M | +27.0% |
| Q1 FY2025 | Mar 31, 2025 | €49.23M | +50.3% |
| Q4 FY2024 | Dec 31, 2024 | €52.94M | +26.4% |
| Q3 FY2024 | Sep 30, 2024 | €45.82M | +20.4% |
| Q2 FY2024 | Jun 30, 2024 | €38.06M | -5.4% |
| Q1 FY2024 | Mar 31, 2024 | €32.75M | -2.3% |
| Q4 FY2023 | Dec 31, 2023 | €41.90M | -62.4% |
| Q3 FY2023 | Sep 30, 2023 | €38.07M | -75.7% |
| Q2 FY2023 | Jun 30, 2023 | €40.24M | -43.6% |
| Q1 FY2023 | Mar 31, 2023 | €33.51M | +53.4% |
| Q4 FY2022 | Dec 31, 2022 | €111.40M | -60.0% |
| Q3 FY2022 | Sep 30, 2022 | €156.68M | +601.2% |
| Q2 FY2022 | Jun 30, 2022 | €71.38M | +193.9% |
| Q1 FY2022 | Mar 31, 2022 | €21.85M | -5.9% |
| Q4 FY2021 | Dec 31, 2021 | €278.24M | – |
| Q3 FY2021 | Sep 30, 2021 | €22.35M | – |
| Q2 FY2021 | Jun 30, 2021 | €24.29M | – |
| Q1 FY2021 | Mar 31, 2021 | €23.22M | – |
See a number that looks wrong?